Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TRML

Tourmaline Bio Inc

Sep 16 • 03:10PM ET

20.11

Dollar change +0.84
Percentage change 4.39	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI IWN VXF IBB VTWO IWC ITOT SBIO VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.68	Insider Own	41.81%	Shs Outstand	20.34M	Perf Week	14.42%
Market Cap	515.75M	Forward P/E	-	EPS next Y	-3.50	Insider Trans	0.07%	Shs Float	14.92M	Perf Month	47.15%
Income	-50.72M	PEG	-	EPS next Q	-0.82	Inst Own	65.08%	Short Float	14.32%	Perf Quarter	18.60%
Sales	0.00M	P/S	-	EPS this Y	65.56%	Inst Trans	-7.46%	Short Ratio	9.18	Perf Half Y	-53.43%
Book/sh	13.19	P/B	1.53	EPS next Y	-14.40%	ROA	-20.13%	Short Interest	2.14M	Perf Year	-25.50%
Cash/sh	11.29	P/C	1.78	EPS next 5Y	-	ROE	-20.84%	52W Range	9.18 - 48.31	Perf YTD	-23.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.23%	ROI	-14.99%	52W High	-58.36%	Beta	2.31
Dividend TTM	-	Quick Ratio	46.87	Sales past 5Y	0.00%	Gross Margin	-	52W Low	119.12%	ATR (14)	1.28
Dividend Ex-Date	Oct 20, 2023	Current Ratio	46.87	EPS Y/Y TTM	79.47%	Oper. Margin	0.00%	RSI (14)	70.25	Volatility	9.95% 7.64%
Employees	52	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	58.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	80.55%	Payout	-	Rel Volume	0.73	Prev Close	19.27
Sales Surprise	-	EPS Surprise	3.55%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	232.80K	Price	20.11
SMA20	22.97%	SMA50	29.46%	SMA200	-9.64%	Trades		Volume	149,915	Change	4.39%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-23	Initiated	Jefferies	Buy	$41
Dec-04-23	Resumed	H.C. Wainwright	Buy	$48
Nov-17-23	Initiated	Truist	Buy	$43
Oct-31-23	Initiated	Guggenheim	Buy	$50
Oct-25-23	Initiated	Piper Sandler	Overweight	$65
Oct-20-22	Initiated	H.C. Wainwright	Buy	$18
Jul-05-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20 → $8

Sep-03-24 07:45AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:30AM	Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-02-24 04:30PM	Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 (GlobeNewswire) -8.09%
Jun-27-24 08:05AM	Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer (GlobeNewswire) -5.84%
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
07:10AM	Loading…
May-23-24 07:10AM	Tourmaline Bio to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 07:00AM	Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial (GlobeNewswire)
May-13-24 01:54PM	TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-02-24 07:00AM	Avalo Therapeutics Appoints Biotech Leaders to Board of Directors (GlobeNewswire) -7.39%
Mar-19-24 02:52PM	TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-15-24 08:50AM	Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going (Zacks)
Feb-28-24 08:50AM	Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength (Zacks)
Feb-27-24 07:30AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
08:50AM	Loading…
Feb-08-24 08:50AM	What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing' (Zacks)
Feb-01-24 08:00AM	Tourmaline Bio to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 04:01PM	Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-24 07:00AM	Tourmaline Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +7.33%
Jan-24-24 04:05PM	Tourmaline Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire) -6.37%
Jan-08-24 07:00AM	Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD) (GlobeNewswire) +9.25%
Dec-15-23 04:00PM	Tourmaline Bio added to the NASDAQ Biotechnology Index (GlobeNewswire) -5.00%
Dec-14-23 07:30AM	Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board (GlobeNewswire)
Nov-01-23 08:00AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-26-23 09:02PM	CEO Sandeep Kulkarni Buys 9650 Shares of Tourmaline Bio Inc (GuruFocus.com) +5.83% +7.03%
Oct-19-23 05:37PM	Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million (GlobeNewswire) -59.93%
Oct-17-23 05:47PM	Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio (GlobeNewswire) -6.00%
Oct-06-23 05:09PM	Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio (GlobeNewswire)
Oct-04-23 08:30AM	New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics (GlobeNewswire)
Jun-22-23 07:30AM	Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement (GlobeNewswire) +22.73%
07:00AM	Loading…
May-26-23 07:00AM	Talaris Therapeutics Announces Leadership Transition (GlobeNewswire)
May-20-23 08:18AM	Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30% (Simply Wall St.)
Feb-16-23 03:10PM	Wellesley biotech cuts one-third of staff, explores sale (American City Business Journals) +24.05%
07:00AM	Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan (GlobeNewswire)
Dec-25-22 09:25AM	We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-22-22 07:00AM	Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-10-22 07:00AM	Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update (GlobeNewswire) +6.99%
Nov-07-22 07:00AM	Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance (GlobeNewswire)
Oct-21-22 11:28AM	Talaris (TALS) Down on Patient Death From Renal Transplant Study (Zacks)
Oct-20-22 02:27PM	HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space (Benzinga) -43.39%
10:26AM	Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease (Benzinga)
08:24AM	Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial (MarketWatch)
07:00AM	Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial (GlobeNewswire)
Oct-17-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting (GlobeNewswire) +6.96%
Oct-04-22 07:00AM	Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-21-22 07:00AM	Talaris Therapeutics to Present at William Blairs Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event (GlobeNewswire)
Sep-06-22 07:00AM	Talaris Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +6.19%
Aug-15-22 07:00AM	Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update (GlobeNewswire)
Jul-18-22 09:47AM	We Think Talaris Therapeutics (NASDAQ:TALS) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-30-22 07:00AM	Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update (GlobeNewswire) -36.75%
Jun-07-22 04:01PM	Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022 (GlobeNewswire) -9.14%
Jun-01-22 07:00AM	Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study (GlobeNewswire)
May-31-22 07:00AM	Talaris Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +16.35%
May-17-22 04:01PM	Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +35.93% -14.51%
07:00AM	Talaris Therapeutics Announces Changes to Board of Directors (GlobeNewswire)
May-12-22 04:01PM	Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update (GlobeNewswire) -5.25%
May-02-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress (GlobeNewswire)
Apr-28-22 11:45AM	10 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global (Insider Monkey)
Apr-06-22 04:01PM	Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001 (GlobeNewswire)
Mar-22-22 04:01PM	Talaris Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire) +5.50%
Mar-17-22 04:01PM	Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results (GlobeNewswire)
Feb-11-22 07:00AM	Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -9.18%
Feb-08-22 01:32PM	We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely (Simply Wall St.)
Jan-31-22 09:38AM	Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ... (GuruFocus.com)
Jan-06-22 07:00AM	Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-22 07:00AM	Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-20-21 07:00AM	Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index (GlobeNewswire) +17.30%
Dec-14-21 07:00AM	Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant (GlobeNewswire)
Nov-30-21 07:00AM	Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma (GlobeNewswire)
Nov-12-21 07:00AM	Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-21 07:00AM	Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-04-21 06:00AM	Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting (GlobeNewswire)
Oct-29-21 07:00AM	Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction (GlobeNewswire) +7.24%
Oct-28-21 04:36PM	Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting (GlobeNewswire)
Sep-02-21 07:00AM	Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences (GlobeNewswire)
Aug-12-21 07:00AM	Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Aug-10-21 08:10AM	Here's What Talaris Therapeutics, Inc.'s (NASDAQ:TALS) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-14-21 04:01PM	Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jun-03-21 07:00AM	Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress (GlobeNewswire)
May-11-21 04:01PM	Talaris Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) -7.26% -7.90%
May-06-21 09:53PM	Talaris Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Sandeep Chidambar	CEO	Aug 21 '24	Buy	14.85	1,779	26,418	7,000	Aug 22 04:22 PM
Kulkarni Sandeep Chidambar	CEO	Aug 16 '24	Buy	13.79	5,221	71,998	5,221	Aug 20 06:09 PM
MCDADE MARK	Director	Jan 29 '24	Buy	32.50	100,000	3,250,000	448,431	Jan 31 04:26 PM
Kulkarni Sandeep Chidambar	CEO	Nov 17 '23	Buy	16.99	4,000	67,960	729,735	Nov 20 06:15 PM
Thiara Parvinder	Director	Nov 17 '23	Buy	17.31	1,000	17,310	83,782	Nov 20 06:14 PM
Castelein Caley	Director	Oct 27 '23	Buy	14.55	15,800	229,890	516,519	Oct 27 05:43 PM
Castelein Caley	Director	Oct 25 '23	Buy	12.07	4,200	50,694	500,719	Oct 27 05:43 PM
Kulkarni Sandeep Chidambar	CEO	Oct 26 '23	Buy	12.25	5,000	61,250	725,735	Oct 26 05:34 PM
Kulkarni Sandeep Chidambar	CEO	Oct 24 '23	Buy	10.68	4,650	49,662	720,735	Oct 26 05:34 PM
KANTOFF AARON	Director	Oct 24 '23	Buy	11.86	7,500	88,950	45,391	Oct 26 05:00 PM
Thiara Parvinder	Director	Oct 24 '23	Buy	10.66	5,000	53,300	80,782	Oct 26 04:46 PM
Thiara Parvinder	Director	Oct 25 '23	Buy	12.12	2,000	24,240	82,782	Oct 26 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRML

Tourmaline Bio Inc

Upgrade your FINVIZ experience